Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months

被引：0
|
作者：
A. D. Anastasilakis
S. A. Polyzos
P. Makras
A. Gkiomisi
I. Bisbinas
A. Katsarou
A. Filippaios
C. S. Mantzoros
机构：
[1] 424 General Military Hospital,Department of Endocrinology
[2] Aristotle University of Thessaloniki,Department of Medicine, Second Medical Clinic, Ippokration General Hospital
[3] 251 Hellenic Air Force & VA General Hospital,Department of Endocrinology and Diabetes
[4] 424 General Military Hospital,Department of Obstetrics and Gynaecology
[5] 424 General Military Hospital,2nd Department of Orthopaedics
[6] Hellenic Military School of Medicine,Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center
[7] Harvard Medical School,undefined
来源：
Osteoporosis International | 2014年 / 25卷
关键词：
Bone metabolism; Denosumab; Fracture; Irisin; Osteoporosis; Teriparatide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1633 / 1642
页数：9
相关论文
共 50 条
  • [31] APPLICATION OF QUANTITATIVE BONE SCAN USING KBONE VALUES TO IDENTIFY REGIONAL BONE METABOLISM CHANGES IN POSTMENOPAUSAL OSTEOPOROTIC WOMEN TREATED EITHER WITH ALENDRONATE OR TERIPARATIDE
    Garg, B.
    Dixit, V.
    Parida, G.
    Sati, H.
    Kumar, R.
    Malhotra, R.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S610 - S611
  • [32] BONE-RELATED OUTCOMES IN SEVERELY OSTEOPOROTIC POSTMENOPAUSAL WOMEN ON DENOSUMAB AFTER A YEAR OF ADD-ON TERIPARATIDE VS. ONGOING MONOTHERAPY
    Kozamernik, K. Mlekus
    Kocjan, T.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S462 - S462
  • [33] Muscular mass (MM) differentiates women with low bone mass (BM) and osteoporotic fractures from those with low BM and no fractures
    Mastaglia, S.
    Bagur, A.
    Oliveri, B.
    Mautalen, C.
    BONE, 2016, 83 : 279 - 279
  • [34] Muscular mass (MM) diferentiates women with low bone mass (BM) and osteoporotic fractures from those with low BM and no fractures
    Mastaglia, Silvina
    Bagur, Alicia
    Oliveri, Beatriz
    Mautalen, Carlos
    JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 : S489 - S489
  • [35] Denosumab improves the structural geometry of the proximal femur in postmenopausal women with low bone mass.
    Beck, T. J.
    Miller, P. D.
    Lewiecki, E. M.
    Felsenberg, D.
    Sun, L.
    Libanati, C.
    Liu, Y.
    Fitzpatrick, L. A.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S71 - S71
  • [36] Denosumab and Alendronate Have Different Effects at the Ultradistal Radius in Postmenopausal Women With Low Bone Mass
    Libanati, Cesar
    Seeman, Ego
    Thomas, Thierry
    Boyd, Steven
    Boutroy, Stephanie
    Shane, Elizabeth
    Hanley, David
    Bogado, Cesar
    Cheung, Angela
    Majumdar, Sharmila
    Sellmayer, Deborah
    Kearns, Ann
    Delmas, Pierre
    Fan, Michelle
    Zanchetta, Jose
    BONE, 2010, 46 : S28 - S29
  • [37] Hip structural analysis of the proximal femur in postmenopausal women with low bone mass treated with denosumab
    Felsenberg, D.
    Miller, P. D.
    Lewiecki, E. M.
    Libanati, C.
    Liu, Y.
    Beck, T. J.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S9 - S9
  • [38] Mineral and Organic Matrix Content at Bone Forming Surfaces in Postmenopausal Women Treated with Either Teriparatide or Zoledronic Acid for 6 Months.
    Paschalis, Eleftherios P.
    Dempster, David W.
    Gamsjaeger, Sonja
    Klaushofer, Klaus
    Taylor, Kathleen A.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S272 - S273
  • [39] Not all postmenopausal women on chronic steroid and estrogen treatment are osteoporotic: Predictors of bone mass
    Lane, NE
    Thompson, JT
    Arnaud, CD
    ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 364 - 364
  • [40] PREVENTING BONE LOSS IN POSTMENOPAUSAL WOMEN WITH LOW BONE MASS AND LOW-TRAUMA FOREARM FRACTURES
    Cirstoiu, M.
    Cirstoiu, C.
    Popescu, D.
    Popescu, A.
    Ene, R.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : S647 - S648
12345